- Chris Woolston
- Posted March 11, 2013
As most people with diabetes know well, wildly fluctuating levels of sugar in the bloodstream can cause trouble. High levels of blood sugar, due to a lack of insulin or resistance to insulin, reflect the body's inability to transport sugar into its cells to be used as fuel. The cells literally begin starving to death -- a process that can lead to kidney disease, heart disease, chronic infections, and a host of other ailments. But with proper treatment, patients with diabetes can bring their blood sugar under control. While some people can achieve that control through diet and exercise, many will need extra help. Thanks to modern medicine, help isn't hard to find.
Doctors who treat diabetes can choose from a long list of effective medications, including some that have just hit the market. When taken properly, diabetes medications can lower your blood sugar level, reduce your symptoms, and lessen your risk of diabetic complications, such as nerve damage and vision loss. Remember though, that no matter what diabetes drugs you take, it's still crucial to get regular exercise and follow a meal plan.
Here's an overview of currently available treatments:
Insulin, a natural hormone, is essential to clear the sugar (glucose) from the foods you eat from your bloodstream and distribute it throughout the cells of your body. It also helps your body convert that sugar into energy. Since people with type 1 diabetes are unable to make the hormone on their own, they need regular doses of insulin -- either injected multiple times per day or delivered through an implanted pump.
Injections of insulin are also an effective weapon against type 2 diabetes. Insulin may be prescribed as a first-line defense, but it's most often used when oral drugs fail to do the job. Your doctor will work with you to come up with the most effective drug regimen for yourself.
Commonly, a shot of insulin at bedtime is combined with an oral drug during the day. Insulin comes in many different forms. Some act quickly, while others take longer to kick in. A new form of insulin can be inhaled rather than injected (it is not yet available for general use, however). Your doctor may prescribe a combination of insulins to give you maximum control.
Whatever kind of insulin you take, you'll have to carefully time your injections and closely monitor your blood sugar to avoid hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar).
Here's a quick look at the different types of insulin:
Regular insulin lowers blood sugar in 30 minutes after a subcutaneous injection and lasts for five to seven hours. The peak effect is at two and a half to five hours. Examples include Humulin R and Novolin R.
Humalog (Insulin lispro) is a genetically engineered, quick-acting compound that starts lowering blood sugar within 15 minutes of subcutaneous injection, peaks in about 30-90 minutes and keeps working for three to five hours. This type of insulin is injected within 15 minutes before or right after a meal (compared with 30 minutes for regular insulin), allowing for greater flexibility. However, it may have to be injected more often than regular insulin.
Humulin N, Novolin N (NPH) are intermediate-acting insulins. They start working in one to four hours, reach a peak between four and 14 hours, and last quite a bit longer than regular insulin or Humalog, from 10 to 24 hours. These intermediate-acting insulins have replaced lente insulin, which is no longer available in the United States because of its limited use.
Lantus (insulin glargine) lasts for 24 hours and unlike other forms of insulin, it works steadily throughout the day without any pronounced peaks. This may reduce the risk of hypoglycemia. The glucose-lowering activity of the drug begins in one and a half hours after subcutaneous injection.
Levemir (insulin detemir), like Lantus, is another long-acting insulin that doesn't peak but works evenly over a 5- to 24-hour period. Approved by the FDA in 2005, it takes several hours for the drug to begin working.
Inhaled insulin is available in experimental form called Afrezza. At least one study indicates it's as effective as injected forms of the drug. However, the FDA still has to approve Afrezza for general use.
If you have type 2 diabetes, your doctor may prescribe an oral drug to control your blood sugar. Many of these drugs affect insulin, which clears sugar from the blood. Some increase the production of insulin, while others increase your body's sensitivity to the insulin that's already there. (Because people with type 1 diabetes make little or no insulin, they won't benefit from these medications.) If your blood sugar is still too high, your doctor may prescribe a combination of drugs.
No single type of medication works best for all patients. Your doctor will choose a drug that fits your particular needs. (It's important to let the doctor know if you are pregnant or taking other medications or herbs, which might interact with your new medications.) Whichever drug (or drug combination) is prescribed, follow the instructions to the letter, and be sure to ask your doctor about potential side effects.
You can find out how your medication is working by checking your blood glucose (sugar) at the times outlined by your doctor or health care provider. If your blood glucose or HbAlc is within the target range most of the time, your medicine regimen is working. If not, contact your physician or provider.
Oral medications for diabetes come in several different classes. Below are examples of some of the more common medications in use today:
In use for the last 40 years, sulfonylureas treat type 2 diabetes when nutrition and exercise alone aren't enough to control blood sugar. They increase the production of insulin and help your body make use of the hormone. Here are some drugs included in this category:
GENERIC NAME -- BRAND NAME
Glimepiride -- Amaryl
Glipizide -- Glucotrol
Glyburide -- DiaBeta, Micronase
Possible side effects of these drugs include hypoglycemia (low blood sugar),upset stomach, rarely weight gain, and allergic reactions in people who have an allergy to sulfa medicines.
Biguanides improve glucose tolerance and decrease the amount of glucose made by your liver.
GENERIC NAME -- BRAND NAME
Metformin -- Glucophage, Fortamet, Glucophage XR
This medicine is less likely to cause hypoglycemia when compared to sulfonylureas, but it can cause diarrhea, nausea, vomiting, and abdominal discomfort especially when taken on an empty stomach.
These drugs slow down the absorption of sugar into the blood and make you more sensitive to insulin. They are often used in combination with other diabetes medications.
GENERIC NAME -- BRAND NAME
Acarbose -- Precose
Miglitol -- Glyset
Alpha-glucosidase inhibitors are taken with meals. Common side effects include gastrointestinal distress, including gas and diarrhea. Let your physician know if these symptoms persist more than a few weeks. Sometimes these problems can be avoided by beginning with a lower dose and increasing it gradually. People with severe bowel or kidney disease or liver disorders should not take this medication.
This type of medication makes your cells more sensitive to insulin and decreases the amount of glucose secreted by the liver. It is sometimes given in combination with metformin (see Biguanides, above).
GENERIC NAME -- BRAND NAME
Pioglitazone -- Actos
Possible liver problems are a concern with these drugs. It is important for your doctor to check your liver regularly if you take thiazolidinediones. These drugs may also cause weight gain, edema, and swelling. If you experience unusual nausea, vomiting, abdominal pain, severe fatigue, or dark urine, call your doctor immediately. One drug of this type, troglitazone, was withdrawn from the market in the fall of 2000.
In September 2010, the Food and Drug Administration severely restricted the use of another drug, Avandia, because controlled clinical trials showed a significant increase in heart attack risk and death for patients using the drug. It is supposed to be used only in patients with type 2 diabetes who cannot control their disease on other medications, and the American Diabetes Association has issued a consensus statement advising doctors not to prescribe it.
This type of drug stimulates the pancreas to produce more insulin. Glinides are fast acting and short-lived, allowing greater flexibility in meal timing.
GENERIC NAME -- BRAND NAME
Repaglinide -- Prandin
Nateglinide -- Starlix
When taken with meals, these drugs decrease the risk of hypoglycemia. Glinides act similarly to sulfonylureas in the way they control blood sugar, but in clinical studies repaglinide appears to be more potent than nateglinide.
A single pill that combines a biguanide with a sulfonylurea (Glucovance) or a biguanide with a thiazolidinedione (ActoPlus Met, Avandamet) can increase the effectiveness of insulin using different mechanisms in the body. Biguanides decrease insulin production through the liver, sulfonylureas increase insulin production through the pancreas, and thiazolidinediones increase overall insulin sensitivity.
GENERIC NAME -- BRAND NAME
Glyburide and metformin -- Glucovance
Pioglitazone and metformin -- ActoPlus Met
Rosiglitazone and metformin -- Avandamet
Glucovance is approved for use by people with type 2 diabetes and is generally well tolerated. With Glucovance, some patients develop hypoglycemia but the episodes are mostly mild. Some patients develop mild diarrhea or an upset stomach, but this usually goes away in a few weeks; very rarely, patients may develop increased sensitivity to the sun. However, Glucovance shouldn't be taken by anyone with kidney disease or a history of liver disease, who drinks heavily, or who has a serious condition such as a severe infection.
Nausea, diarrhea, and headache are the most common side effects for people taking Avandamet. Chest infection, diarrhea, and nausea are common side effects with ActoPlus Met. Both Avandamet and ActoPlus Met have FDA boxed warnings and may cause or worsen heart failure. People with type 1 diabetes, children, and pregnant women should not use either of these drugs.
American Diabetes Association 800/342-2382
National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease
Food and Drug Administration. FDA significantly restricts access to the diabetes drug Avandia. Sept. 23, 2010 http://www.fda.gov/newsevents/newsroom/pressannouncements/UCM226975.htm
Fujimoto WY. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care. 2000 Apr;23 Suppl 2:B11-3.
The Diabetes Monitor: Troglitazone. Warner-Lambert voluntarily withdraws Rezulin. March 28, 2000. http://www.diabetesmonitor.com/rezulin.htm. Also: http://www.warner-lambert.com/press/release.asp?release=109
All our patients need to know about intensified diabetes management they learned in fourth grade. Diabetes Educ. 2000 May-Jun;26(3):392-4, 396, 400-2 passim.
Food and Drug Administration. FDA Consumer. Insulin Key to Diabetes But Not Full Cure. May 1992. http://www.fda.gov/bbs/topics/CONSUMER/CON00137.html
About Insulin. American Diabetes Association. http://www.diabetes.org/type-2-diabetes/insulin.jsp
American Diabetes Association. Diabetes forecast. January 2005. http://www.diabetes.org/uedocuments/rg05insulins.pdf
Food and Drug Administration. FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes. January 2006. http://www.fda.gov/bbs/topics/news/2006/NEw01304.html
Food and Drug Administration. FDA Issues Safety Alert on Avandia. May 2007. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html
Clinical Pharmacology Online Drug Monographs. GoldStandard. Accessed 25 Nov 2008.
Food and Drug Administration. Patient Information Sheet: Insulin Detemir (rDNA origin) Injection (marketed as Levemir). July 2005. http://www.fda.gov/cder/consumerinfo/druginfo/Levemir.htm
American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice. Volume 13 (Supp 1). May/June 2007.
Food and Drug Administration. Avandamet. http://www.fda.gov/cder/foi/label/2008/021410s025lbl.pdf
Food and Drug Administration. Pioglitazone HCI Information for Healthcare Professionals. August 2007. http://www.fda.gov/CDER/Drug/InfoSheets/HCP/pioglitazoneHCP.htm
Food and Drug Adminstration. ActoPlus Met. December 2008. http://www.fda.gov/cder/foi/label/2009/021842s007lbl.pdf
Rosenstock J, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. The Lancet. Vol. 375, Issue 9733 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60632-0/abstract
Health News is provided as a service to Shelby Drugstore, Inc. site users by HealthDay. Shelby Drugstore, Inc. nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.
Copyright © 2019 HealthDay All Rights Reserved.